FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122797075> ?p ?o ?g. }

• W2122797075 endingPage "284" @default.
• W2122797075 startingPage "284" @default.
• W2122797075 abstract "To evaluate the efficacy of the combination of interferon alpha (IFN-alpha) and daily low-dose cytarabine (ara-C) in the treatment of patients with early chronic-phase chronic myelogenous leukemia (CML) (within 1 year of diagnosis). Improving the degree of hematologic and cytogenetic response in patients with Philadelphia chromosome (Ph)-positive CML may improve prognosis. Both IFN-alpha and ara-C induce cytogenetic responses as single-agent therapy in CML.One hundred forty patients with Ph-positive early chronic-phase CML received subcutaneous injections of IFN-alpha 5 megaunits/m2 daily and ara-C 10 mg daily. Their median age was 46 years; 53% had good-risk disease, 33% had intermediate-risk disease, and 14% had poor-risk disease. Their results were compared with those of patients receiving IFN-alpha with or without intermittent ara-C (7 days/mo).A complete hematologic response (CHR) was achieved in 92% of patients. A cytogenetic response was seen in 74%: it was major in 50% (Ph-positive < 35%) and complete in 31% (Ph-positive 0%). With a median follow-up of 42 months, the 4-year estimated survival rote was 70% (95% confidence interval, 61% to 79%). Significant side effects included fatigue (43%; grade 3/4, 11%), weight loss (19%; grade 3/4, 11%), muscle and bone aches (20%; grade 3/4, 7%), oral ulcers (4%), diarrhea (6%), and neurologic changes (27%, grade 3/4, 6%). The median dose of IFN-alpha was 3.7 megaunits/m2 daily, mainly because of reductions for myelosuppression (70% of cases); the median ara-C dose was 7.5 mg daily. Prognostic risk groups were predictive for response to the IFN-alpha plus ara-C combination. The incidence of CHR was higher with IFN-alpha plus daily ara-C compared with IFN-alpha plus intermittent ara-C and IFN-alpha alone (no ara-C) (92% v 84% v 80%, P = .01), as were the incidences of cytogenetic response (74% v 73% v 58%; P = .003) and major cytogenetic response (50% v 38% v 38%; P = .06). The median time to achievement of major cytogenetic response was significantly shorter than that for previous IFN-alpha regimens (7 v 10 v 12 months; P < .01). However, with the present follow-up, the survival and time to blastic transformation were similar.The combination of IFN-alpha plus daily low-dose ara-C seems to be promising for the treatment of CML. High rates of CHR and cytogenetic response were observed with acceptable toxicity and a lower daily dose of IFN-alpha compared with our previous studies." @default.
• W2122797075 created "2016-06-24" @default.
• W2122797075 creator A5011529063 @default.
• W2122797075 creator A5011548707 @default.
• W2122797075 creator A5015140142 @default.
• W2122797075 creator A5016607292 @default.
• W2122797075 creator A5027575595 @default.
• W2122797075 creator A5028026524 @default.
• W2122797075 creator A5030171128 @default.
• W2122797075 creator A5057701424 @default.
• W2122797075 creator A5061285204 @default.
• W2122797075 creator A5070096873 @default.
• W2122797075 creator A5073798523 @default.
• W2122797075 creator A5079262854 @default.
• W2122797075 creator A5090435894 @default.
• W2122797075 date "1999-01-01" @default.
• W2122797075 modified "2023-10-18" @default.
• W2122797075 title "Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine" @default.
• W2122797075 cites W1498708301 @default.
• W2122797075 cites W186063976 @default.
• W2122797075 cites W188630774 @default.
• W2122797075 cites W1901923962 @default.
• W2122797075 cites W1928548710 @default.
• W2122797075 cites W1972804480 @default.
• W2122797075 cites W1985163185 @default.
• W2122797075 cites W1989333836 @default.
• W2122797075 cites W1992798892 @default.
• W2122797075 cites W199915037 @default.
• W2122797075 cites W2001524759 @default.
• W2122797075 cites W2004568784 @default.
• W2122797075 cites W2006518962 @default.
• W2122797075 cites W2010012100 @default.
• W2122797075 cites W2025574559 @default.
• W2122797075 cites W2038990138 @default.
• W2122797075 cites W2039978091 @default.
• W2122797075 cites W2058190985 @default.
• W2122797075 cites W2076372887 @default.
• W2122797075 cites W2255425975 @default.
• W2122797075 cites W2268722580 @default.
• W2122797075 cites W2269564684 @default.
• W2122797075 cites W2337277825 @default.
• W2122797075 cites W236820854 @default.
• W2122797075 cites W2438648923 @default.
• W2122797075 cites W2465903784 @default.
• W2122797075 cites W2508058084 @default.
• W2122797075 cites W2512753555 @default.
• W2122797075 cites W38386901 @default.
• W2122797075 cites W4255256991 @default.
• W2122797075 cites W4293241248 @default.
• W2122797075 cites W60081501 @default.
• W2122797075 cites W977069352 @default.
• W2122797075 doi "https://doi.org/10.1200/jco.1999.17.1.284" @default.
• W2122797075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10458244" @default.
• W2122797075 hasPublicationYear "1999" @default.
• W2122797075 type Work @default.
• W2122797075 sameAs 2122797075 @default.
• W2122797075 citedByCount "133" @default.
• W2122797075 countsByYear W21227970752012 @default.
• W2122797075 countsByYear W21227970752013 @default.
• W2122797075 countsByYear W21227970752014 @default.
• W2122797075 countsByYear W21227970752015 @default.
• W2122797075 countsByYear W21227970752016 @default.
• W2122797075 countsByYear W21227970752017 @default.
• W2122797075 countsByYear W21227970752021 @default.
• W2122797075 countsByYear W21227970752023 @default.
• W2122797075 crossrefType "journal-article" @default.
• W2122797075 hasAuthorship W2122797075A5011529063 @default.
• W2122797075 hasAuthorship W2122797075A5011548707 @default.
• W2122797075 hasAuthorship W2122797075A5015140142 @default.
• W2122797075 hasAuthorship W2122797075A5016607292 @default.
• W2122797075 hasAuthorship W2122797075A5027575595 @default.
• W2122797075 hasAuthorship W2122797075A5028026524 @default.
• W2122797075 hasAuthorship W2122797075A5030171128 @default.
• W2122797075 hasAuthorship W2122797075A5057701424 @default.
• W2122797075 hasAuthorship W2122797075A5061285204 @default.
• W2122797075 hasAuthorship W2122797075A5070096873 @default.
• W2122797075 hasAuthorship W2122797075A5073798523 @default.
• W2122797075 hasAuthorship W2122797075A5079262854 @default.
• W2122797075 hasAuthorship W2122797075A5090435894 @default.
• W2122797075 hasConcept C104317684 @default.
• W2122797075 hasConcept C126322002 @default.
• W2122797075 hasConcept C138626823 @default.
• W2122797075 hasConcept C141071460 @default.
• W2122797075 hasConcept C185592680 @default.
• W2122797075 hasConcept C203014093 @default.
• W2122797075 hasConcept C2776178377 @default.
• W2122797075 hasConcept C2776960273 @default.
• W2122797075 hasConcept C2778041864 @default.
• W2122797075 hasConcept C2778461978 @default.
• W2122797075 hasConcept C2778904597 @default.
• W2122797075 hasConcept C2909179924 @default.
• W2122797075 hasConcept C55493867 @default.
• W2122797075 hasConcept C71924100 @default.
• W2122797075 hasConcept C90924648 @default.
• W2122797075 hasConceptScore W2122797075C104317684 @default.
• W2122797075 hasConceptScore W2122797075C126322002 @default.
• W2122797075 hasConceptScore W2122797075C138626823 @default.
• W2122797075 hasConceptScore W2122797075C141071460 @default.

• next